A disease that produces no warning signs remains unknown
A decades-long study of more than 134,000 people has revealed that MASLD — a silent liver disease affecting roughly one in five UK residents — becomes dramatically more lethal when accompanied by high blood pressure, type 2 diabetes, or low HDL cholesterol. These three cardiometabolic conditions, already widespread in modern populations, each compound the risk of dying from the disease, with high blood pressure alone raising mortality by 40 percent. The findings arrive as cases climb among children and younger adults, urging medicine to look beyond the liver and treat the whole metabolic picture before the silence of the disease becomes irreversible.
- A liver disease with no symptoms is quietly advancing in 80% of those who carry it, leaving millions unaware they are accumulating risk with every passing year.
- Three common conditions — high blood pressure, type 2 diabetes, and low HDL cholesterol — act as accelerants, pushing MASLD mortality risk up by as much as 40% when present alongside the disease.
- Children are not spared: cases of MASLD in young people have doubled over two decades, signaling that this is no longer a disease of aging or excess drinking but of modern diet and sedentary life.
- Researchers are calling for a reordering of clinical priorities, urging that patients carrying cardiometabolic risk factors be screened and treated earlier, before compounding dangers converge.
- Routine blood tests already offer a detection window — the obstacle is not the science but whether healthcare systems will commit to using it at the scale the disease now demands.
A silent liver disease is proving far deadlier than previously understood when it shares the body with three common heart-related conditions. Analyzing data from over 134,000 people across thirty years, researchers found that high blood pressure, type 2 diabetes, and low HDL cholesterol each significantly amplify the risk of dying from MASLD — a condition in which fat accumulates in the liver, unrelated to alcohol consumption. High blood pressure alone raises mortality risk by 40 percent, diabetes by 25 percent, and low HDL by 15 percent, with each additional risk factor stacking another 15 percent on top.
What gives the findings particular weight is how invisible MASLD remains. It produces few or no symptoms, and roughly 80 percent of those who have it don't know. Most discover it incidentally, during blood work ordered for something else entirely. The British Liver Trust estimates one in five UK residents carries the disease; some experts place the true figure closer to 40 percent.
Lead researcher Dr. Matthew Dukewich noted that blood pressure has been underestimated as a threat in MASLD patients — a blind spot the study now corrects. His colleague Dr. Norah Terrault pointed toward the clinical implication: those carrying cardiometabolic risk factors alongside MASLD face the highest danger and should be first in line for intervention.
The disease is also spreading into younger populations. Cases among children have doubled over twenty years, driven by sedentary habits and diets rich in processed foods, salt, and sugar. With 4.6 million people in the UK now living with type 2 diabetes and 14 million with high blood pressure, the conditions that make MASLD lethal are themselves becoming more common. The path forward, researchers suggest, runs through routine screening — catching the disease before the convergence of silent factors turns quietly dangerous.
A liver disease that silently accumulates fat in the organ is now understood to be far more lethal when paired with common heart conditions. Researchers studying over 134,000 people across three decades have identified the dangerous trio: high blood pressure, type 2 diabetes, and low HDL cholesterol—each one dramatically amplifying the risk of death from metabolic dysfunction-associated steatotic liver disease, or MASLD.
The numbers are stark. High blood pressure alone raises the mortality risk by 40 percent. Type 2 diabetes adds another 25 percent. Low HDL cholesterol contributes 15 percent. And each additional metabolic risk factor compounds the danger by another 15 percent. This is not the liver disease of heavy drinkers. MASLD develops when fat simply accumulates inside the liver, a process increasingly common in populations eating ultra-processed foods and living sedentary lives.
What makes this discovery particularly urgent is how invisible the disease remains. About 80 percent of people with MASLD have no idea they have it. The condition produces no symptoms, or symptoms so mild they blend into the background of ordinary life. Most people discover they have it by accident—during a routine blood test or liver function screening done for some other reason. The British Liver Trust estimates that one in five people in the UK carry the disease. Some experts believe the true figure could reach 40 percent.
Dr. Matthew Dukewich, a transplant hepatology fellow at the University of Southern California and lead author of the study, noted a significant shift in medical understanding. Until recently, doctors focused primarily on diabetes as the main threat to MASLD patients. Blood pressure, it turns out, deserves equal attention. His colleague Dr. Norah Terrault emphasized that the findings point toward new priorities for clinical care—areas where intervention could meaningfully improve outcomes.
The disease is no longer confined to older populations. Cases among children have doubled over the past two decades. Younger adults are developing MASLD at rising rates, a trend experts attribute to sedentary behavior and diets heavy in salt, sugar, and processed fats. In the UK alone, 4.6 million people now have type 2 diabetes—a record high—and approximately 14 million adults live with high blood pressure, a number that continues to climb.
The research suggests a clear path forward: patients with MASLD who also carry cardiometabolic risk factors should be prioritized for medical attention. They face the highest mortality risk and stand to benefit most from early intervention. Yet the challenge remains detection itself. A disease that produces no warning signs and often goes undiagnosed for years cannot be managed if it remains unknown. Routine blood work offers a window—a simple, accessible way to identify the condition before it advances. The question now is whether healthcare systems will act on this knowledge, screening populations at risk and catching MASLD before the combination of factors turns it truly dangerous.
Citações Notáveis
Until now, diabetes was thought to be the main danger for MASLD patients, but blood pressure is now seen as equally important— Dr. Matthew Dukewich, lead author, University of Southern California
The study shows new areas where doctors should focus to help patients with MASLD get better care— Dr. Norah Terrault, co-author, University of Southern California
A Conversa do Hearth Outra perspectiva sobre a história
Why does blood pressure matter so much for a liver disease? They seem unrelated.
They're connected through metabolism. High blood pressure signals that your cardiovascular system is under stress, and that same stress affects how your liver processes fat. When both systems are struggling, the liver becomes more vulnerable.
But 80 percent of people don't know they have it. How do you treat something nobody knows about?
That's the crisis embedded in this story. You can't treat what you don't see. The disease is silent by design—no pain, no obvious warning. Most people stumble onto their diagnosis by accident.
The numbers keep climbing in younger people. What changed?
Our lives changed. We sit more, move less, eat foods engineered to be hyper-palatable and calorie-dense. A teenager today faces metabolic pressures that didn't exist a generation ago.
If one in five people have it, why isn't this a public health emergency?
It is, but it doesn't look like one. Emergencies are visible—they have symptoms, they fill hospitals. MASLD is a slow accumulation happening inside millions of people right now, unnoticed.
What would actually change things?
Routine screening. Make blood tests standard, not exceptional. Catch it early, before the dangerous combinations develop. And help people understand that this isn't about willpower or shame—it's about how modern life is reshaping our bodies.